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Abstract
Introduction: In the recent years comorbidity has been discussed as a factor affecting therapeutic decisions, the course of tre-
atment, and prognosis of patients with lung cancer. The aim of the study was 1. to evaluate the occurrence of comorbidities in 
patients with lung cancer undergoing surgery, and 2. to investigate the utility of Charlson Comorbidity Index (CCI) and Simplified 
Comorbidity Score (SCS) for preoperative evaluation of Polish patients with lung cancer.
Material and methods: The retrospective study included 476 patients with lung cancer, who underwent surgical treatment. In all 
patients, data on histopathological type of the tumor, stage, history of smoking, comorbidities, and spirometric parameters were 
collected. CCI and SCS scores were calculated. The presence of comorbidities was analyzed in relation to sex, histology, and stage 
of lung cancer. Correlations between CCI and SCS scores and age, number of pack-years, spirometric parameters were assessed.
Results: The most prevalent comorbidities were hypertension (42%), chronic obstructive pulmonary disease (COPD) (22%), 
coronary heart disease (17%), and diabetes (12%). There were no differences in the distribution of comorbidity depending on the 
histological type and stage of lung cancer. The CCI and SCS scores showed correlations with age, number of pack-years and 
spirometric parameters, however, their compounds do not reflect the profile of most prevalent comoribidities.
Conclusion: The burden of comorbidity among patients with lung cancer is significant. Comorbidity should be assessed while 
considering patients for surgical treatment. However, the CCI and SCS do not seem precise enough for this purpose.
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Introduction
Currently, lung cancer is the most common 
cause of death from neoplasms [1, 2]. The main 
determinants of the patient’s eligibility for sur-
gical treatment are as follows: the stage of the 
tumor, performance status (PS), and pulmonary 
function parameters. In the recent years also 
comorbidity has been investigated as a  factor 
affecting the therapeutic decisions, the course of 
treatment, and prognosis of patients with lung 
cancer [3]. The problem concerns a substantial 
number of patients because in this population, 
the risk of chronic diseases is high due to age 
and smoking history. It has been proven that the 
presence of comorbidities has an impact on the 
decisions of physicians qualifying patients for 
oncological treatment [4]. There is also evidence 
that comorbidity could increase the risk of adver-
se events during the therapy [5, 6], including 
surgery [6, 7]. The impact of these disorders on 
prognosis varies depending on the stage of lung 
cancer. In patients in the early stages, undergoing 
radical treatment, their influence on the prognosis 
is significant [8, 9]. In contrast, in the advanced 
stage of the disease, the predominant impact on 
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survival has lung cancer itself [10, 11]. For the 
purposes of the assessment before treatment, as 
well as in patients participating in clinical trials, 
the use of numerical scales quantifying comor-
bidities is often suggested. Currently, the most 
commonly used scales are Charlson Comorbidity 
Index (CCI) and Simplified Comorbidity Score 
(SCS). The CCI was developed in 1987 based on the 
survival analysis of 599 patients hospitalized for 
various medical conditions and was later valida-
ted on a group of patients with breast cancer [12]. 
The CCI includes a list of 19 diseases and a score 
they are assigned depending on their impact on 
mortality. The highest scores in this scale has 
been assigned to such diseases as AIDS, metasta-
tic solid tumor or severe liver disease. Cardiologic 
problems, as well as respiratory and vascular 
diseases are included in common categories, and 
are assigned the lowest scoring [12]. The second 
popular scale, namely SCS is dedicated to the 
assessment of patients with non-small cell lung 
cancer. It includes 7 groups of diseases which 
are assigned scores depending on the impact on 
prognosis [13]. In this scale, in turn, the greatest 
negative impact on prognosis has been attributed 
to smoking, defined as consumption of 100 ciga-
rettes in patient’s  lifetime; likewise in the CCI, 
cardiovascular and pulmonary diseases have 
a significantly lower weight. 
The utility of these scales in predicting the 
course of treatment and outcome has been inve-
stigated. However, the results of studies on the 
topic are often divergent; some of them confirm 
the value of the CCI and SCS as prognostic indi-
cators in patients with lung cancer [9, 13–15]. It 
has been shown, for example, that high scoring 
in both scales (CCI ≥ 3, SCS > 9) is an indepen-
dent negative prognostic factor in patients with 
lung cancer [14]. On the contrary, studies which 
question their value and indicate that sufficient 
information is provided, for instance, by PS can 
also be found [10, 11, 16]. The issue of the optimal 
tool for the assessment of comorbidity coexisting 
with lung cancer still remains open. Nevertheless, 
due to the significant burden of chronic diseases 
in this group of patients, the thorough preopera-
tive assessment of comorbidity might presumably 
be of importance in considering the patients for 
surgical treatment.
In the present cross-sectional study, our aim 
was to evaluate the occurrence of comorbidities 
in patients with lung cancer undergoing surgery 
and to investigate the prevalence of these diseases 
depending on sex, histopathological type, and 
stage of lung cancer. We also aimed to confront 
our findings with the compounds of the CCI and 
SCS in order to assess whether the scales can 
sufficiently represent comorbidity in the Polish 
population of patients with lung cancer. 
Material and methods
Study group 
The retrospective study included 476 pa-
tients (327 men and 149 women) diagnosed with 
lung cancer who underwent surgical treatment 
between January 2012 and September 2013. The 
inclusion criteria comprised the diagnosis of lung 
cancer and positive qualification for the surgical 
treatment. In order to perform a real-life study, 
we included into the study group all patients who 
underwent surgery for lung cancer within a given 
period of time. In all patients, the histopathologi-
cal type of cancer and stage of the disease (TNM 
classification, 7th edition [17]) were evaluated. 
Patients were divided into three groups according 
to histopathology: with squamous cell carcinoma, 
adenocarcinoma, and other histopathological ty-
pes. History of smoking (number of pack-years) 
and the presence of comorbidities (coronary heart 
disease, hypertension, myocardial infarction, 
peripheral vascular disease, atrial fibrillation and 
other arrhythmias, COPD, tuberculosis, diabetes, 
stroke, thyroid diseases, malignancy) were retro-
spectively obtained from the medical history and 
available medical records of the patients at the 
time of admission. Forced spirometry performed 
during the qualification for surgery was taken into 
account. Forced expiratory volume in one second 
(FEV1) and vital capacity (VC) are presented as 
a percentage of the predicted value. In all patients, 
comorbidity scores were calculated according to 
CCI and SCS.
Methods 
The presence of comorbidities was analyzed 
in subgroups according to sex, histology of the 
tumor and stage of lung cancer. Correlations 
between CCI, SCS scores and age, number of pac-
k-years, spirometric parameters were assessed, 
depending on gender, histopathological type, and 
the stage of cancer. Scoring in the CCI and SCS 
was analyzed as a continuous and dichotomous 
variable (for the CCI scores < 3 and ≥ 3 and for the 
SCS scores ≤ 9 and > 9 [14]). Quantitative varia-
bles are presented with the following descriptive 
statistics: mean (range, SD) or median (IQR) for 
variables with non-Gaussian distribution, and the 
variable quality on a numbers (n) and percenta-
ges. For the quantitative variables compliance 
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Table 1. Histopathological diagnoses grouped as “other 
histopathological types”
Other histopathological types of tumors n %
Large cell carcinoma
Carcinoid (typical and atypical)
Bronchioloalveolar carcinoma 
Non-small cell carcinoma (not otherwise 
specified, NOS)
Small cell carcinoma 
pleomorphic carcinoma 
Sarcomatoid carcinoma 
Neuroendocrine carcinoma  
Adenosquamous carcinoma  
Basaloid carcinoma
Spindle cell carcinoma
Carcinoma adenoides cysticum
21
13
9
7
5
4
3
3
1
1
1
1
4
3
2
1
1
1
0,5
0,5
< 0,1
< 0,1
< 0,1
< 0,1
with a normal distribution was tested using the 
Shapiro-Wilk test. The homogeneity of variance 
was examined by the Kolmogorov-Smirnov test. 
To examine differences between groups for quan-
titative variables with Gaussian distribution and 
homogeneous variance Student’s t test was used. 
With non-gaussian distribution or non-homoge-
nous variance Mann-Whitney U test was used. 
To examine the relationship between variables 
of gaussian distribution Pearson’s test was usted. 
In the case where one of the variables had non-
gaussian distribution, Spearman test was used. 
To examine differences between groups using 
qualitative variables Pearson Chi2 test was used. 
Cluster analysis was performed by k-means. The 
level of significance was set at p = 0.05. Statistical 
analyzes were performed using Statistica 10.0. 
For this type of study (retrospective study) formal 
consent of the ethics review board is not required. 
Results
Statistics of the study group
A group of 476 patients operated for lung 
cancer (327 men, 149 women) was evaluated. The 
mean age was 63.7 (min 22, max 84; SD 7,9). About 
94% of the group were smokers (current or former) 
and 6% nonsmokers. The mean number of pack- 
-years was 45.5 min 0, max 138; SD 22,25); there 
was a statistically significant difference between 
men and women in the number of pack-years (wo-
men: mean 34,72, 0-102, SD 17,8; men: mean 50,06, 
0-138, SD 22,4; U Mann-Whitney test p = 0.000). 
Spirometric parameters (FEV1, VC) were 
analyzed as percent of the predicted value. In 
the total group the mean FEV1 was 83% and the 
mean VC was 93%. In men the mean values were 
as follows: FEV1 82%, VC 89%; in women 85% 
and 101%, respectively. The differences of VC 
between men and woman appeared statistically 
significant (U Mann-Whitney test p = 0.01). The 
mean FEV1 in patients with squamous cell carci-
noma was slightly lower (80%) than in patients 
with adenocarcinoma (86%) and other histopa-
thological types (85%). The same regularity was 
related to VC (91% vs 94% and 94%), but the dif-
ferences were not found statistically significant. 
Patients with squamous cell carcinoma com-
prised 45% of the group (n = 215), with adenocar-
cinoma 40% (n = 190), the other histopathological 
types 15% (n = 71). The other histopatological ty-
pes of tumors are summed up in the table (Table 1). 
There were no significant differences in the 
distribution of histological types between men 
and women.
Detailed data of the study group are summa-
rized in Table 2.
The occurrence of comorbidities
In the study group, the most prevalent co-
morbidities were as follows: hypertension (42% 
of patients), COPD (22%), coronary heart disease 
(17%), and diabetes (12%). Some statistically si-
gnificant differences in the prevalence of certain 
comorbidities between women and men were 
observed. In women, thyroid diseases were more 
frequent (15% vs. 2%, Pearson Chi2 p < 0.05), 
while in men, peripheral arterial disease (10% 
vs. 4%, Pearson Chi2 p < 0.05) and myocardial 
infarction (12% vs. 5%, Pearson Chi2 p < 0.05) 
were found more prevalent. In the whole study 
group, hypertension was the most common co-
morbid disease in both genders, in patients at all 
stages of cancer, and in all histopathological types 
(p < 0.05) (Figs 1, 2).
The analysis of comorbidities depending 
on the histological type of lung cancer showed 
no statistically significant differences; however, 
some trends were apparent for more frequent 
occurrence of certain diseases. For example, 
COPD was slightly more common in patients 
with squamous cell carcinoma (Pearson Chi2 
p = 0.07) (Fig. 2).
There were no differences in the distribution 
of comorbidities depending on the stage of lung 
cancer.
To determine the distribution of comorbi-
dities in the study group, cluster analysis by 
k-means has been conducted. We eliminated 
from the cluster analysis the comorbidities that 
occurred least often or have not affected the 
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Figure 2. The presence of comorbidities depending on the histopathological type of tumor
Figure 1. The presence of comorbidities depending on gender
differences between the clusters. The analysis 
included the following diseases: hypertension 
(HTN), COPD, coronary heart disease (CHD), 
myocardial infarction (MI), peripheral vascular 
disease (PVD) and diabetes mellitus (DM). Two 
clusters of patients appeared, which differed 
in the incidence of cardiovascular diseases 
and diabetes. The cluster 1 comprised 365 pa-
tients, and the cluster 2 comprised 111 patients. 
The occurrence of comorbid diseases in both 
clusters is shown on the graph (Fig. 3). The 
incidence of COPD in both groups was similar, 
which can be related to dominance of smokers 
in the study group. The clusters have been 
compared in terms of gender, age, histological 
diagnosis and history of smoking. Patients in 
the cluster 2, in which the incidence of cardiac 
disease and diabetes was higher, were older 
than patients in cluster 1 (p < 0.05). The mean 
age of patients in the cluster 1 was 62.7 (22–83, 
SD = 8.01), in the cluster 2 66.7 (51–84, SD = 
6.88). There were no differences in terms of 
gender, histopathological diagnoses and the 
number of pack-years.
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Table 2.  Characteristics of the study group. Statistically 
significant differences between subgroups are 
marked with U Mann-Whitney test
Characteristics of the study group n %
Population
   women 
   men
476
149
327
100
31
69
Histopathological type of cancer
   squamous cell carcinoma
   adenocarcinoma
   other histopathological types
215
190
71
45
40
15
Stage of lung cancer (TNM, 7th edition)
   IA
   IB
   IIA
   IIB
   IIIA
   IIIB, IV
71
97
111
49
112
28
15
21
24
10
24
6
Smoking history
   current or former smokers
   non-smokers
448
28
94
6
Mean Range SD
Age
   total group
   women
   men
63.70
63.60
63.74
22–84
22–77
29–84
7.9
7.6
8.1
Number of pack-years
   total group
   women
   men 
   squamous cell carcinoma
   adenocarcinoma
   other histopathological types
45.5 
34.92* 
50.06*
48.39
44.53
38.64
0–138
0–102*
0–138*
0–138
0–120
0–86
22.25
17.8*
22.4*
22.7
22.7
20.19
Spirometric parameters
FEV1 (% pred.)
   total group
   women
   men 
   squamous cell carcinoma
   adenocarcinoma
   other histopathological types
VC (% pred)
   total group
   women
   men 
   squamous cell carcinoma
   adenocarcinoma
   other histopathological types
83
85
82
80
86
85
93
101*
89*
91
94
94
*p < 0.05
Evaluation of CCI and SCS scores
CCI
In the whole study group, the median CCI 
score was 0 (IQR 0-1). There were no significant 
differences between men and women. In the 
entire group, there was a statistically significant 
positive correlation of the CCI score with age and 
the number of pack-years and a negative corre-
lation with spirometric parameters (VC, FEV1) 
(Spearman’s rank correlation, p < 0.05) (Table 3). 
About 6.7% of the study group (n = 32) 
achieved a CCI score ≥ 3. This group of patients 
had a significantly higher number of pack-years 
history (mean 53.8, 0-126; SD 27.1) compared to 
patients with the CCI < 3 (mean 44.7; 0-138; SD 
21.6) (U Mann-Whitney test, p < 0.05), without 
any differences in terms of age and spirometric 
parameters. There were no differences between 
men and women when it comes to the distribution 
of CCI scores < 3 and ≥ 3. Moreover, no associa-
tion could be observed between the tumor stage 
or histopathological type and the CCI score.
SCS
The median SCS score was 8 (IQR 7–9). In 
the whole study group, there was a statistically 
significant positive correlation of SCS score with 
age and the number of pack-years and a negative 
correlation with spirometric parameters (Spear-
man’s rank test, p < 0.05). There was a significant 
difference between the SCS scores in men and 
woman (U Mann-Whitney test, p = 0.01). 
About 12.1% of the study group (n = 58) achie-
ved an SCS score >9. Patients in this group were 
Figure 3. Cluster analysis of the prevalence of comorbidities in the 
study group. The prevalence of the comorbid diseases is presented 
as percentages. COPD — chronic obstructive pulmonary disease; 
HTN — arterial hypertension; CHD — coronary heart disease; MI 
— myocardial infarction; PVD — peripheral vascular disease; DM — 
diabetes mellitus
older and were characterised by worse spirome-
tric parameters compared to the group of SCS ≤ 9 
(U Mann-Whitney test p < 0.05), while there was no 
significant difference when it comes to the history 
of smoking. There were no differences between men 
and women in distribution of SCS scores ≤ 9 and 
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Table 3.  Correlations coefficients between scores in the CCI and SCS, and patients’ age, number of pack-years and spiro-
metric parameters
CCI SCS
test r p test r p
Age Spearman’s rank correlation 0.17 0.0001 Spearman’s rank correlation 0.19 0.000
VC (% pred) Spearman’s rank correlation –0.16 0.0005 Spearman’s rank correlation –0.16 0.000
FEV1 (% pred) Spearman’s rank correlation –0.20 0.000 Spearman’s rank correlation –0.16 0.000
Number of pack-years Spearman’s rank correlation 0.10 0.0397 Spearman’s rank correlation 0.16 0.0007
p < 0.05 was considered statistically significant; CCI — Charlson Comorbidity Index; SCS — Simplified Comorbidity Score; FEV1 — forced expiratory volume in one 
second; VC — vital capacity
Table 4.  Evaluation of the study group in the CCI and SCS. CCI and SCS are presented as medians (IQR). Age and pack- 
-years are presented as means (range, SD). FEV1 and VC are presented as mean percentages. Statistically signi-
ficant differences between subgroups are marked with U Mann-Whitney test
Evaluation of the study group in the CCI and SCS
Scoring in the scales CCI (median, IQR) SCS (median, IQR)
Total group
   women
   men
Squamous cell carcinoma
Adenocarcinoma
Other histopathological types
0 (0–1)
0 (0–1)
0 (0–1)
1 (0–1)
0 (0–1)
1 (0–1)
8 (7–9)
8 (7–9)
8 (7–9)
8 (7–9)
8 (7–8)
8 (7–9)
Characteristics of subgroups according to CCI scoring CCI < 3 (n = 444) 
(mean, range, SD)
CCI ≥ 3 (n = 32)
(mean, range, SD)
Age
Pack-years
FEV1 (% pred)
VC (% pred)
63.66 (22–84; 8.03)
44.7 (0–138; 21.6)*
83%
93%
64 (52–77; 6.71)
53.8 (0–126; 27.1)* 
83%
90%
Characteristics of subgroups according to SCS scoring SCS ≤ 9 (n = 418)
(mean, range, SD)
SCS > 9 (n = 58)
(mean, range, SD)
Age 
Pack-years 
FEV1 (% pred)
VC (% pred)
63.27 (22–83; 8.03)*
44.8 (0–138; 22.5)
83% 
93%*
66.79 (55–84; 6.52)* 
50.2 (10–117; 19.9)
80%
88%* 
*p < 0.05; CCI — Charlson Comorbidity Index; SCS — Simplified Comorbidity Score; FEV1 — forced expiratory volume in one second; VC — vital capacity
 > 9. Likewise, no association was found between 
tumor stage or histopathological type and the 
SCS score.
Details of the CCI and SCS assessment are 
shown in Tables 3 and 4.
To sum up the characteristics of the two 
groups with the highest burden of comorbidity 
according to the CCI and SCS, we found that pa-
tients with the CCI score ≥ 3 were characterised 
by a higher number of pack-years than patients 
with CCI < 3, and patients with the SCS score > 9 
were older and had worse spirometric parameters 
than patients with the SCS ≤ 9.
Discussion
In the current study, we attempted to describe 
a group of patients operated for lung cancer in 
terms of incidence of comorbidities. Moreover, 
our aim was to assess some commonly used nu-
merical scales quantifying chronic diseases for 
their suitability for preoperative assessment of 
patients with lung cancer. We analysed a large 
group of patients scheduled for surgery (n = 
476), which is comparable to previous data 
regarding Polish patients with lung cancer in 
terms of age and history of smoking [18]. Pa-
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tients in the early stages of cancer dominated 
in the study group, which is understandable in 
the context of the planned radical surgical tre-
atment. Patients in stages IIIB and IV accounted 
for a total of 6%, which is a result of intraope-
rative re-staging.
While considering surgery in patients with 
lung cancer, a number of factors characterising 
the patient, including stage of the tumour, PS, 
and lung function parameters, are usually taken 
into account [19, 20]. Patients with lung cancer, 
mostly elderly people and heavy smokers, are at 
particular risk of chronic diseases. This can be 
seen in the study group in which high proportion 
of current or former smokers (94%) and high ave-
rage number of pack-years (45.5) translates into 
a high prevalence of tobacco-related diseases. 
Indeed, the most prevalent disorders observed 
in our study (hypertension, COPD) occur more 
frequently than it has been reported for the Po-
lish population (respectively, 42% vs. 29% [21], 
22% vs. 10% [22, 23]. It has been observed that 
these diseases as tobacco-related disorders, 
tend to coexist [24]. Some differences in the 
occurrence of comorbidity between men and 
women were also shown (e.g., higher incidence 
of myocardial infarction and peripheral arterial 
disease in men), which may be associated with 
a significantly higher number of pack-years in 
men. Differences in the coexistence of various 
histological types of lung cancer and chronic 
diseases were insignificant. Higher incidence of 
COPD in patients with squamous cell carcinoma 
can be attributed to a particularly strong associa-
tion of this histological type with smoking [25]. 
We have also shown significantly higher inciden-
ce of cardiovascular comorbidities in older pa-
tients with lung cancer, which indicates the need 
for particularly careful preoperative assessment 
in this group of patients. 
The term “comorbidity” refers to somatic and 
mental disorders, independent from lung cancer, 
which may affect the safety of the treatment and 
outcome. It should be distinguished from the term 
“performance status” (PS), most widely used in 
oncology, describing the patient’s ability to per-
form daily activities. The low PS may result from 
both the cancer itself and comorbidity; however, 
it has been proven that these traits should be con-
sidered independently [26]. Moreover, the assess-
ment of PS by a physician is highly subjective. In 
this analysis, the PS is not included because the 
examined patients were characterized by high PS 
(0–1), and therefore this parameter did not give 
any additional information.
For numerical description of comorbidity, 
two most widely used scales were applied: CCI 
and SCS. Correlations between scores in these 
scales and patients’ age, history of smoking, and 
deterioration of spirometric parameters were 
observed. To sum up the evaluation of the study 
group in the CCI and SCS, we can say that the 
highest scores obtained in the examined scales 
applies to elderly patients, with worse spirome-
tric parameters and heavy smokers. However, 
no correlation was found between the burden 
of comorbidities and the stage of lung cancer or 
histopathological type.
Opinions on the prognostic value of the CCI 
and SCS vary [9–11, 13–16]. The scales differ si-
gnificantly in terms of their components and the 
weight each component of the scale is assigned. 
Currently, the CCI is used most widely. Note, 
however, that this scale has been used for nearly 
30 years, and the impact of its individual compo-
nents on the prognosis has changed during this 
time concurrently with the progress of diagnostics 
and therapy of particular conditions comprising 
the scale (an example might be AIDS, which is 
assigned the highest score in the scale). Simi-
larly, the SCS puts the greatest emphasis on to 
smoking which is defined as consumption of 100 
cigarettes in the patient’s lifetime [13] and which 
seems out of proportion to much lower scoring of 
cardiovascular or respiratory diseases. From the 
standpoint of the clinician qualifying patients for 
surgery, the high incidence of COPD and cardio-
vascular diseases observed in our study seems 
to be essential. Globally increasing mortality 
due to COPD is well known [27]. It has been also 
proven that the occurrence of this single disease 
adversely affected prognosis of patients operated 
for lung cancer [28]. Similarly, the coexistence of 
cardiovascular disease has been associated with 
a higher rate of postoperative complications in 
such patients [29, 30]. However, in both CCI and 
SCS these diseases are of minor importance and 
their impact on prognosis is marginalised. Mo-
reover, hypertension, a condition most commonly 
observed in our study group is not considered in 
the CCI at all. It seems, therefore, that the use 
of these scales, at least for the contemporary 
Polish population of patients with lung cancer 
may lead to underestimation of operational risk 
associated with the occurrence of respiratory an 
cardiovascular diseases. In other cases the use of 
these scales may result in assigning an excessive 
risk, for example in patients with a history of 
smoking but without significant tobacco-related 
diseases, assessed in the SCS. Thus, although 
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consideration of chronic diseases in preoperative 
assessment of patients with lung cancer appears 
to be reasonable, in our opinion the CCI and SCS 
do not seem sufficient for this purpose.
A limitation of the present study is the lack 
of information about the long-term survival of the 
study group, due to the retrospective character 
of the study and lack of follow-up information. 
Further studies on the impact of comorbidities on 
survival of patients with lung cancer are necessa-
ry, especially as the data for the Polish population 
on the topic are scarce.
Conclusions 
In conclusion, the present study revealed 
a significant burden of comorbidity among pa-
tients with lung cancer, higher than in the general 
population. Thus, comorbidity should be asses-
sed while considering this group of patients for 
surgical treatment. Scoring in two popular scales 
quantifying comorbidity, CCI and SCS, correlates 
with some patients’ characteristics commonly 
considered by physicians, such as age, smoking 
history and spirometric parameters. However, the 
CCI and SCS scales do not reflect the profile of 
comorbidity in patients with lung cancer suffi-
ciently, and therefore do not seem precise enough 
for this purpose.
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